THE DEAL, AT A GLANCE
From the announcementAPTADIR
01Who is involvedBacked by the Italian Research National Council (CNR), the Cancer Science Institute of Singapore Milan, 4BIO Capital</strong>From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedAPTADIR raised Seed, announced 2026-09-29From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersAptadir’s €40M seed financing supports development of RNA inhibitor-based therapeutics intended to reverse silenced genes in intractable genetic conditions.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
APTADIR · Financing Record
Explore source-linked visual explanations for APTADIR. Unsupported claims are withheld while source review continues.
Record 13055 · Recorded date: 2026-09-29
Explore company records →